Insights

Rationale for Anti-Angiogenesis in Lung Cancer
June 22, 2017 – 
Roy S. Herbst, MD, PhD, explains the clinical rationale and mechanism of action for anti-angiogenesis therapy in advanced lung cancer.
Role of Immunotherapy in Lung Cancer
June 22, 2017 – 
Roy S. Herbst, MD, PhD, offers his perspectives on the role of immunotherapy in advanced lung cancer.
Deciding on Second-Line Lung Cancer Therapy
June 09, 2017 – 
Roy S. Herbst, MD, PhD, reviews patient selection criteria for second-line therapy in nondriver lung adenocarcinoma.
Frontline Decision Making in Nondriver Lung Cancer
June 09, 2017 – 
Roy S. Herbst, MD, PhD, explains his clinical decision making in the frontline and maintenance settings in patients with lung cancer who lack a driver mutation.
Outcomes-Based Contracting in Lung Cancer
June 06, 2017 – 
John Fox, MD, MHA, outlines outcomes-based contracting in lung cancer, including the potential benefits and pitfalls.
Cost-Benefit Analysis in Lung Cancer
June 06, 2017 – 
In this segment, John Fox, MD, MHA, discusses factors that affect the payer cost-benefit analysis and the challenges with adherence in lung cancer.
Drug Monitoring and Reversal Agents for Direct Oral Anticoagulants
June 02, 2017 – 
Michael B. Bottorff, PharmD, discusses the appropriateness for drug monitoring and reversal agents with the use of direct oral anticoagulants.
Differentiation of Direct Oral Anticoagulants for NVAF
June 02, 2017 – 
In this segment, Michael B. Bottorff, PharmD, remarks on the differentiation of direct oral anticoagulants for use in nonvalvular atrial fibrillation.
Current Biomarkers in Lung Cancer
June 01, 2017 – 
Roy S. Herbst, MD, PhD, provides an overview of the most relevant predictive mutations in lung cancer and the clinical utility of PD-L1 expression.
Use of Warfarin in Nonvalvular Atrial Fibrillation
May 30, 2017 – 
Michael B. Bottorff, PharmD, remarks on the role of warfarin use in preventing stroke in patients with nonvalvular atrial fibrillation.
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!